FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020344127> ?p ?o ?g. }

• W2020344127 endingPage "608" @default.
• W2020344127 startingPage "601" @default.
• W2020344127 abstract "PURPOSE To evaluate the importance of angiogenesis in plaque progression after stent placement, this study examines stent-based controlled delivery of the antiangiogenic agent, angiostatin, in a rabbit model. MATERIALS AND METHODS Controlled release biodegradable microspheres delivering angiostatin or polymeronly microspheres (polylactic-co-glycolic-acid–polyethylene glycol; PLGA/PEG) were loaded in channeled stents, anchored, and deployed in the aorta of adult New Zealand white rabbits (n = 6 animals per group, three each per time point). The stented aortas were harvested at 7 days and 28 days and evaluated for neovascularization, local inflammation, vascular smooth muscle cell proliferation, and in-stent plaque progression. RESULTS At 7 days, neovascularization was significantly decreased in the angiostatin groups (1.6 < 1.6 neovessels per mm2 plaque) versus the control group (15.4 ± 2.6 neovessels per mm2 plaque; P = .00081), as were local inflammation where angiostatin-treated groups demonstrated significantly lower macrophage recruitment per cross section (34.9 ± 4.9 cells per cross section) relative to the control group (55.2 ± 3.84 cells per cross section; P = .0037). And a significant decrease in the overall vascular smooth muscle cell proliferation (143.8 ± 26.3 Ki-67 positive cells per mm2) relative to the control group (263.2 ± 16.6 Ki-67 positive cells per mm2; P = .00074). At both 7 and 28 days, in-stent plaque progression in the angiostatin groups was successfully limited relative to the control group by 54% (0.255 ± 0.019% of cross section; P = .00016) and 19% (1.981 ± 0.080; P = .0033) respectively and resulted in reduction of in-stent restenosis relative to the control group. CONCLUSIONS Angiostatin-eluting stents may limit neovascularity after arterial implantation, offer insight into in-stent restenosis, and allow future refinement of bioactive stent designs and clinical strategies, particularly in light of evidence that intimal smooth muscle cells may in part be marrow-derived. To evaluate the importance of angiogenesis in plaque progression after stent placement, this study examines stent-based controlled delivery of the antiangiogenic agent, angiostatin, in a rabbit model. Controlled release biodegradable microspheres delivering angiostatin or polymeronly microspheres (polylactic-co-glycolic-acid–polyethylene glycol; PLGA/PEG) were loaded in channeled stents, anchored, and deployed in the aorta of adult New Zealand white rabbits (n = 6 animals per group, three each per time point). The stented aortas were harvested at 7 days and 28 days and evaluated for neovascularization, local inflammation, vascular smooth muscle cell proliferation, and in-stent plaque progression. At 7 days, neovascularization was significantly decreased in the angiostatin groups (1.6 < 1.6 neovessels per mm2 plaque) versus the control group (15.4 ± 2.6 neovessels per mm2 plaque; P = .00081), as were local inflammation where angiostatin-treated groups demonstrated significantly lower macrophage recruitment per cross section (34.9 ± 4.9 cells per cross section) relative to the control group (55.2 ± 3.84 cells per cross section; P = .0037). And a significant decrease in the overall vascular smooth muscle cell proliferation (143.8 ± 26.3 Ki-67 positive cells per mm2) relative to the control group (263.2 ± 16.6 Ki-67 positive cells per mm2; P = .00074). At both 7 and 28 days, in-stent plaque progression in the angiostatin groups was successfully limited relative to the control group by 54% (0.255 ± 0.019% of cross section; P = .00016) and 19% (1.981 ± 0.080; P = .0033) respectively and resulted in reduction of in-stent restenosis relative to the control group. Angiostatin-eluting stents may limit neovascularity after arterial implantation, offer insight into in-stent restenosis, and allow future refinement of bioactive stent designs and clinical strategies, particularly in light of evidence that intimal smooth muscle cells may in part be marrow-derived." @default.
• W2020344127 created "2016-06-24" @default.
• W2020344127 creator A5001237553 @default.
• W2020344127 creator A5007329975 @default.
• W2020344127 creator A5021876301 @default.
• W2020344127 creator A5029533113 @default.
• W2020344127 creator A5029782605 @default.
• W2020344127 creator A5037533038 @default.
• W2020344127 creator A5039298082 @default.
• W2020344127 creator A5042349927 @default.
• W2020344127 creator A5066504801 @default.
• W2020344127 creator A5073025604 @default.
• W2020344127 creator A5087025541 @default.
• W2020344127 creator A5087512336 @default.
• W2020344127 date "2004-06-01" @default.
• W2020344127 modified "2023-10-18" @default.
• W2020344127 title "Stent-based Controlled Release of Intravascular Angiostatin to Limit Plaque Progression and In-Stent Restenosis" @default.
• W2020344127 cites W1561059299 @default.
• W2020344127 cites W1576437441 @default.
• W2020344127 cites W1600542667 @default.
• W2020344127 cites W1968220875 @default.
• W2020344127 cites W1986834835 @default.
• W2020344127 cites W1992451903 @default.
• W2020344127 cites W1996217732 @default.
• W2020344127 cites W1996270335 @default.
• W2020344127 cites W2000000541 @default.
• W2020344127 cites W2000872098 @default.
• W2020344127 cites W2004132222 @default.
• W2020344127 cites W2005760229 @default.
• W2020344127 cites W2009240587 @default.
• W2020344127 cites W2015784049 @default.
• W2020344127 cites W2020828434 @default.
• W2020344127 cites W2022718682 @default.
• W2020344127 cites W2023472206 @default.
• W2020344127 cites W2026351725 @default.
• W2020344127 cites W2026673368 @default.
• W2020344127 cites W2027033388 @default.
• W2020344127 cites W2031845199 @default.
• W2020344127 cites W2043297474 @default.
• W2020344127 cites W2043863730 @default.
• W2020344127 cites W2048083227 @default.
• W2020344127 cites W2059541988 @default.
• W2020344127 cites W2072928113 @default.
• W2020344127 cites W2075333521 @default.
• W2020344127 cites W2076552301 @default.
• W2020344127 cites W2083630382 @default.
• W2020344127 cites W2084818589 @default.
• W2020344127 cites W2093447087 @default.
• W2020344127 cites W2098273775 @default.
• W2020344127 cites W2104182514 @default.
• W2020344127 cites W2118879463 @default.
• W2020344127 cites W2121203285 @default.
• W2020344127 cites W2121594719 @default.
• W2020344127 cites W2131798870 @default.
• W2020344127 cites W2151426663 @default.
• W2020344127 cites W2152639592 @default.
• W2020344127 doi "https://doi.org/10.1097/01.rvi.0000127888.70058.93" @default.
• W2020344127 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15178721" @default.
• W2020344127 hasPublicationYear "2004" @default.
• W2020344127 type Work @default.
• W2020344127 sameAs 2020344127 @default.
• W2020344127 citedByCount "23" @default.
• W2020344127 countsByYear W20203441272012 @default.
• W2020344127 countsByYear W20203441272013 @default.
• W2020344127 countsByYear W20203441272014 @default.
• W2020344127 countsByYear W20203441272015 @default.
• W2020344127 countsByYear W20203441272018 @default.
• W2020344127 countsByYear W20203441272019 @default.
• W2020344127 countsByYear W20203441272022 @default.
• W2020344127 crossrefType "journal-article" @default.
• W2020344127 hasAuthorship W2020344127A5001237553 @default.
• W2020344127 hasAuthorship W2020344127A5007329975 @default.
• W2020344127 hasAuthorship W2020344127A5021876301 @default.
• W2020344127 hasAuthorship W2020344127A5029533113 @default.
• W2020344127 hasAuthorship W2020344127A5029782605 @default.
• W2020344127 hasAuthorship W2020344127A5037533038 @default.
• W2020344127 hasAuthorship W2020344127A5039298082 @default.
• W2020344127 hasAuthorship W2020344127A5042349927 @default.
• W2020344127 hasAuthorship W2020344127A5066504801 @default.
• W2020344127 hasAuthorship W2020344127A5073025604 @default.
• W2020344127 hasAuthorship W2020344127A5087025541 @default.
• W2020344127 hasAuthorship W2020344127A5087512336 @default.
• W2020344127 hasConcept C106812560 @default.
• W2020344127 hasConcept C126322002 @default.
• W2020344127 hasConcept C142724271 @default.
• W2020344127 hasConcept C185592680 @default.
• W2020344127 hasConcept C202751555 @default.
• W2020344127 hasConcept C2776914184 @default.
• W2020344127 hasConcept C2778271429 @default.
• W2020344127 hasConcept C2778283817 @default.
• W2020344127 hasConcept C2778583881 @default.
• W2020344127 hasConcept C2780165375 @default.
• W2020344127 hasConcept C2780394083 @default.
• W2020344127 hasConcept C55493867 @default.
• W2020344127 hasConcept C71924100 @default.
• W2020344127 hasConceptScore W2020344127C106812560 @default.
• W2020344127 hasConceptScore W2020344127C126322002 @default.
• W2020344127 hasConceptScore W2020344127C142724271 @default.

• next